Title

Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI

Document Type

Article

Publication Date

10-1-2018

Publication Title

Journal of thrombosis and thrombolysis

Abstract

Randomized controlled trials (RCTs) examining warfarin use for stroke prevention in atrial fibrillation (AF) may not accurately reflect real-world populations. We aimed to determine the representativeness of the RCT populations to real-world patients and to describe differences in the characteristics of trial populations from trial eligible patients in a real-world setting. We hypothesized that a significant fraction of real-world patients would not qualify for the RE-LY, ROCKET-AF, and ARISTOTLE trials and that real-world patients qualifying for the studies may have more strokes and bleeding events. We compared the inclusion and exclusion criteria, patient characteristics, and clinical outcomes from RE-LY, ROCKET-AF, and ARISTOTLE against data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI

Medical Subject Headings

Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Michigan; Patient Selection; Quality Improvement; Randomized Controlled Trials as Topic; Registries; Thromboembolism; Treatment Outcome; Warfarin

PubMed ID

29948756

Volume

46

Issue

3

First Page

316

Last Page

324

Share

COinS